SSA
BCAX

Schonfeld Strategic Advisors’s Bicara Therapeutics BCAX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-504,085
Closed -$7.96M – 2713
2025
Q3 		$7.96M Buy
504,085
+241,334
+92% +$2.7M 0.05% 422
2025
Q2 		$2.44M Sell
262,751
-103,213
-28% -$1.23M 0.02% 876
2025
Q1 		$4.77M Buy
+365,964
New +$4.86M 0.03% 541

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Schonfeld Strategic Advisors's BCAX Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Bicara Therapeutics (BCAX) in Q4 2025, closing a stake of 504,085 shares — an estimated $7.96M sold.

Schonfeld Strategic Advisors first reported a position in BCAX in Q1 2025 and held it in 3 quarters. The position peaked at $7.96M in Q3 2025. 141 funds tracked by Wall St. Rank hold BCAX as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Bicara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 504,085 Bicara Therapeutics shares in Q4 2025, an estimated $7.96M.
  • Schonfeld Strategic Advisors first reported a position in Bicara Therapeutics in Q1 2025 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Bicara Therapeutics position peaked at $7.96M in Q3 2025.
  • 141 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.